Abbott Laboratories Earnings - Q1 2026 Analysis & Highlights
Abbott Laboratories reported Q1 2026 results marked by strategic acquisition integration, mixed operational performance across segments, and cautious guidance reflecting near-term headwinds offset by long-term growth catalysts in diagnostics, medical devices, and specialty pharmaceuticals.
Key Financial Results
Adjusted earnings per share of $1.15, consistent with guidance despite earlier-than-planned financing costs from the Exact Sciences acquisition and a weaker-than-expected respiratory season.
Comparable sales growth of 3.7% on a comparable basis, which includes full quarter sales of Exact Sciences in both prior and current year periods.
Adjusted earnings per share grew 6% compared to the prior year.
Foreign exchange had a favorable year-over-year impact of 4% on first quarter sales.
Adjusted gross margin of 56.3% of sales, adjusted R&D of 6.7% of sales, and adjusted SG&A of 29.3% of sales.
Business Segment Results
Diagnostics sales increased 2% on a comparable basis, with Core Lab Diagnostics growth of 3% driven by growth in the US, Europe, and Latin America.
Core Lab diagnostic tests sales increased on both a year-over-year and sequential basis, with a trend expected to continue and drive higher growth in the second half of the year compared to the first half.
Rapid and Molecular Diagnostics sales declined 10%, reflecting lower demand for respiratory virus testing due to a much weaker respiratory season compared to last year.
Cancer Diagnostics sales grew 13% on a comparable basis, driven by mid-teens growth of Cologuard and high-teens growth in international markets.
Nutrition sales finished slightly ahead of expectations for the quarter, reflecting lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in Q4 2025.
EPD pharmaceutical business sales increased 9% in the quarter, with broad-based growth across markets including double-digit growth in several countries across Latin America and Asia Pacific regions.
Medical Devices sales grew 8.5%, led by strong performance in cardiovascular device businesses.
Electrophysiology growth of 13% included contributions from two pulsed field ablation catheter launches, with Volt PFA catheter contributing to 14% growth in the US and TactiFlex Duo catheter driving mid-teens growth in Europe.
Rhythm Management sales grew 13%, marking the third consecutive quarter of double-digit growth.
Heart Failure growth of 12% was driven by the market-leading portfolio of heart assist devices.
Continuous glucose monitoring sales were $2 billion and grew 7.5%, with growth reflecting an impact from a delay in the renewal process related to an international tender and a challenging comparison to last year.
Capital Allocation
Exact Sciences acquisition closed on March 23, 2026, adding a new high-growth business to the Abbott portfolio and expanding presence into cancer diagnostics.
Acquisition of Exact Sciences forecast to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.
Industry Trends and Dynamics
CGM market estimated at 70 million to 80 million people globally who should be on CGMs, with current market penetration at 10 million to 12 million people.
Colorectal cancer screening remains significantly under-penetrated, with 50 million Americans not up-to-date with CRC screening.
Colonoscopy capacity remains fixed at approximately 6 million procedures per year, creating a bottleneck as demand for screening increases.
Average wait time for colonoscopy is between three to nine months, depending on the state, indicating existing backlog.
Screening guidelines lowered the recommended age from 50 to 45 in 2021, adding new patients to the addressable market.
Competitive Landscape
Abbott's Electrophysiology business significantly outperforming the market, with double-digit growth in Rhythm Management for three consecutive quarters.
Structural Heart business facing increased competitive intensity in the mitral space as a main competitor expanded their portfolio.
Abbott's Core Lab business achieving high renewal rates of 90-plus percent and win rates of 55-plus percent in new business opportunities.
Cologuard offers 95% sensitivity equivalent to colonoscopy, providing a competitive advantage as an at-home screening option.
Abbott's Volt PFA catheter designed as an upgrade to first-generation products, with conscious sedation aspect providing specific differentiation internationally and in the US.
Macroeconomic Environment
Middle East conflict creating supply chain challenges with shipping lanes becoming congested and increased demand for plane spots and alternative transport methodologies.
Oil cost impact from Middle East conflict too early to determine, with no freight rate increases from suppliers currently observed.
Abbott monitoring cost shocks and maintaining dedicated teams working on gross margin improvement and supplier negotiations.
Weaker-than-expected respiratory season in Q1 compared to historical patterns, with management cautious about forecasting recovery in Q4.
Growth Opportunities and Strategies
Exact Sciences integration proceeding well, with Jake Orville named as new leader reporting directly to CEO, positioned to accelerate the cancer diagnostics business.
Cologuard expansion into international markets leveraging Abbott's established regulatory, KOL, healthcare system distribution, and relationships across multiple markets.
Type 2 non-insulin CGM coverage expected soon, anticipated to add close to 10 million people with new coverage and accelerate commercial coverage.
International CGM expansion opportunities, with only four of the top 10 global markets having full-blown basal coverage, leaving six large markets in evaluation process.
Dual analyte CGM system expected approval in second half of 2026, opening access to approximately 1 million patients previously with limited access on the pump side.
Continuous ketone monitoring for SGLT2 users, with approximately 5 million SGLT2 users not currently using the product who will benefit from continuous ketone monitoring.
Nutrition business pricing actions showing early positive volume response, with volume growth beginning to follow pricing actions implemented in Q4 2025.
New product launches in Nutrition expected to drive growth improvement over the course of the year.
Pipeline achievements in medical devices including earlier-than-planned approval and launch of two new PFA catheters, completion of patient enrollment in CATALYST left atrial appendage device trial, and initiation of development for implantable extravascular ICD product.
Clinical trial readouts planned, including randomized controlled trial demonstrating Type 2 diabetes patients on basal insulin therapy benefit from Libre with reductions in HbA1c and increased time in healthy glucose range.
Multiple clinical trials initiating in second half of 2026, including balloon-expandable TAVR valve, leadless conduction system pacing device, mitral replacement valve, peripheral IVL device, and wearable continuous lactate monitoring sensor for sepsis monitoring.
Financial Guidance and Outlook
Full year 2026 comparable sales growth guidance of 6.5% to 7.5%, on a comparable basis including full year sales of Exact Sciences in both prior and current year.
Full year adjusted earnings per share guidance range midpoint of $5.48, reflecting $0.20 of dilution related to the Exact Sciences acquisition.
Second quarter adjusted earnings per share forecast of $1.25 to $1.31.
Foreign exchange expected to have a favorable impact of approximately 1% on full-year reported sales, with relatively neutral impact expected for the second quarter.
CGM expected to return to double-digit growth in the second quarter.
Electrophysiology business expected to accelerate growth as both Volt and TactiFlex Duo catheters broaden their launches.
Core Lab business expected to achieve mid-single-digit growth rate for the full year, with second half higher than first half.
Structural Heart growth expected to be high single digit for the full year, despite geographic differences persisting for a period.
Management remains confident in acceleration of growth in the second half of the year, with clear visibility to key drivers including Nutrition growth strategy execution, Electrophysiology and Core Lab Diagnostics acceleration, sustained EPD and Medical Devices performance, and Exact Sciences integration.
